Scharf Investments’s Quince Therapeutics QNCX Stock Holding History

Scharf Investments’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-97	Closed	-$1.97K	–	83
2026 Q1	$1.97K	Sell	97 -358	-79%	-$71.9K	﹤0.01%	70
2025 Q4	$305K	Hold	455	–	–	0.01%	69
2025 Q3	$148K	Hold	455	–	–	﹤0.01%	68
2025 Q2	$150K	Hold	455	–	–	﹤0.01%	66
2025 Q1	$121K	Hold	455	–	–	﹤0.01%	69
2024 Q4	$170K	Buy	+455	New	+$137K	0.01%	68
2024 Q2	–	Sell	-455	Closed	-$96.5K	–	63
2024 Q1	$96.5K	Hold	455	–	–	﹤0.01%	59
2023 Q4	$95.6K	Buy	+455	New	+$91.1K	﹤0.01%	56

Scharf Investments's QNCX Position: Q2 2026 in Review

Scharf Investments sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 97 shares — an estimated $1.97K sold.

Scharf Investments first reported a position in QNCX in Q4 2023 and held it in 8 quarters. The position peaked at $305K in Q4 2025. 0 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Scharf Investments reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Scharf Investments sold 97 Quince Therapeutics shares in Q2 2026, an estimated $1.97K.
Scharf Investments first reported a position in Quince Therapeutics in Q4 2023 and held it in 8 quarters.
Scharf Investments's Quince Therapeutics position peaked at $305K in Q4 2025.
0 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Scharf Investments's 13F filing for Q2 2026, filed 13 Jul 2026.